Top 10 Manufacturers of Pharmaceutical Intermediate CAS No. 168828-82-8 in 2025

Understanding CAS No. 168828-82-8 – Docetaxel Side Chain Intermediate

CAS No. 168828-82-8 is a specialized side-chain intermediate used in the synthesis of Docetaxel, a frontline chemotherapy medication. This compound contains the (2R,3S)-3-phenylisoserine moiety in a protected or conjugated form and is involved in the esterification or final coupling steps during Docetaxel assembly.

It is commonly derived from earlier intermediates like CAS 90357-53-2 and plays a vital role in ensuring the correct stereochemistry and bioactivity of the final Docetaxel API.

Importance of CAS No. 168828-82-8 in Oncology Drug Manufacturing

Docetaxel Intermediate with Defined Stereochemistry

This compound contributes the essential chiral side chain to Docetaxel, which is necessary for the drug's anticancer function.

Used in Semi-Synthetic API Processes

Semi-synthesis from 10-Deacetylbaccatin III (10-DAB) incorporates this intermediate in the late-stage coupling step.

Strict GMP and Purity Requirements

It must be produced with high enantiomeric excess and purity, under GMP conditions, to meet injectable formulation standards.

Supports Global Generic Docetaxel Production

With growing demand for affordable chemotherapy, this intermediate is widely used by API manufacturers and CDMOs.

Enables Formulation Flexibility

Its molecular structure can be slightly varied (salt forms, esters) depending on the specific Docetaxel synthesis pathway and regulatory strategy.

Top 10 Manufacturers of CAS No. 168828-82-8

1. Lonza Group

• Location: Basel, Switzerland

• Overview: Lonza is a global leader in oncology intermediates, offering GMP-compliant supply of advanced Docetaxel precursors including CAS 168828-82-8.

• Specialty: High-containment facilities for cytotoxic and chiral synthesis.

2. Bachem AG

• Location: Bubendorf, Switzerland

• Overview: Bachem supplies protected chiral amino acid derivatives and taxane side-chain intermediates at commercial scale.

• Specialty: Precision stereochemistry and analytical documentation.

3. Eastfine

• Location: Changzhou City, Jiangsu Province, China

• Overview: Eastfine delivers pharmaceutical intermediates like CAS 168828-82-8 to global API manufacturers with full COA, MSDS, and export support.

• Specialty: Oncology intermediates with competitive cost and high GMP-grade purity.

4. CordenPharma

• Location: Plankstadt, Germany

• Overview: CordenPharma provides complete taxane intermediate synthesis solutions for branded and generic drug makers.

• Specialty: Late-stage oncology intermediates and sterile-grade compliance.

5. Almac Group

• Location: Craigavon, Northern Ireland

• Overview: Almac supports custom synthesis of Docetaxel side chains, offering scalability and rapid turnaround from pilot to commercial scale.

• Specialty: Oncology-focused CDMO with route development and regulatory support.

6. Olon S.p.A.

• Location: Milan, Italy

• Overview: Olon manufactures protected amino acid intermediates and taxane coupling agents under strict EU regulatory control.

• Specialty: Advanced semi-synthetic intermediates for injectable cytotoxics.

7. Enzymaster Life Sciences

• Location: Düsseldorf, Germany

• Overview: Enzymaster applies biocatalysis to produce highly pure chiral intermediates such as CAS 168828-82-8 with eco-friendly methods.

• Specialty: Green chemistry and enantioselective production of oncology building blocks.

8. Aphios Corporation

• Location: Woburn, Massachusetts, USA

• Overview: Aphios uses supercritical fluid extraction and semi-synthesis to develop taxane intermediates directly from natural sources.

• Specialty: Sustainable Docetaxel intermediate synthesis and formulation research.

9. Carbogen Amcis

• Location: Bubendorf, Switzerland

• Overview: Carbogen Amcis manufactures GMP-grade Docetaxel intermediates under containment, with support for global filings.

• Specialty: Cytotoxic intermediate manufacturing and global CDMO services.

10. Seqens Group

• Location: Ecully, France

• Overview: Seqens supports the global oncology supply chain with custom synthesis and GMP production of late-stage taxane intermediates.

• Specialty: Injectable-quality intermediates with full analytical and regulatory packages.

Trends in the Pharmaceutical Intermediates Market

Growing Taxane API Production

• The rise in generic Docetaxel availability has created a stable demand for well-characterized intermediates like 168828-82-8.

Advanced Stereochemical Techniques

• Suppliers are employing biocatalysis, asymmetric synthesis, and solid-state chemistry to achieve consistent high-purity products.

Shift Toward Integrated CDMO Solutions

• More pharma companies prefer end-to-end service providers that supply intermediates along with API development and regulatory filing support.

Rising Regulatory Scrutiny

• Intermediates involved in cytotoxic synthesis must meet ICH Q11 and FDA expectations for impurity profiling, traceability, and GMP compliance.

Emphasis on Sustainable Manufacturing

• Use of green solvents, enzymatic transformations, and renewable feedstocks is increasing, especially for high-value oncology intermediates.

Conclusion

CAS No. 168828-82-8 is an essential Docetaxel side-chain intermediate, enabling the scalable, GMP-compliant production of one of the world’s most important chemotherapy drugs. As demand for affordable and effective oncology treatments grows, manufacturers such as Lonza, Eastfine, Bachem, and others are ensuring a consistent, high-quality global supply.

Their capabilities in containment, chiral synthesis, and regulatory compliance position them as critical players in advancing cancer treatment worldwide.